Nurix Therapeutics (NRIX) Could Be 20% Below Fair Value After Roche Fueled Profit Turn

Nurix Therapeutics (NRIX) is back in focus after a sharp swing to profitability in its fiscal third quarter, helped by a large Roche collaboration payment and growing momentum behind its bexobrutideg program.

The latest surge in Nurix Therapeutics reflects that story catching more attention, with a 1-day share price return of 5.41% and a 7-day share price move of 12.34% around the earnings and Roche milestones. At the same time, the 1-year total shareholder return of 148.75% and very large 3-year total shareholder return suggest strong momentum has been building for some time.

Spot similar biotech breakouts by scanning our hand-picked 34 healthcare AI stocks that combine clinical catalysts with meaningful recent share price momentum.

Nurix Therapeutics now has cash, partnerships and a late stage bexobrutideg program in motion. After this sharp re rating, does the current share price still fairly reflect that mix of assets and risks?

Most Popular Narrative: 20% Undervalued

The prevailing narrative sees Nurix Therapeutics trading below an implied fair value of $25.00, relative to the last close at $24.95, which puts a lot of weight on how its degrader partnerships and late stage programs play out over time.

The main factor that has to go right is that bexobrutideg and the partnered degrader programs progress through late stage trials in oncology and autoimmune indications under the current collaboration structures with Roche, Sanofi, Gilead and Pfizer.

The figures imply that Nurix Therapeutics is priced for successful execution on its degrader platform and Roche alliance, which is consistent with a view that the stock is fairly valued with a bullish skew to potential outcomes.

See why 0 investors see Nurix Therapeutics as 0% undervalued.

Result: Fair Value of $25.00 (UNDERVALUED)

Still, that fairness story can crack if Roche or other partners slow trials, or if high development spending keeps Nurix Therapeutics posting heavy quarterly losses.

Find out about the key risks to this Nurix Therapeutics narrative.

Next Steps

Mixed signals around Nurix Therapeutics can either sharpen your thinking or blur it, so move quickly, review the numbers, and weigh the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Nurix Therapeutics?

If Nurix Therapeutics has your attention, do not stop here. The real edge often comes from comparing a few strong candidates side by side.

• Target potential mispricing by scanning a curated set of companies with strong fundamentals using the 33 high quality undervalued stocks.
• Protect your downside first by reviewing a 32 resilient stocks with low risk scores that focuses on resilience and cleaner risk profiles.
• Get ahead of the crowd by filtering for a 20 high quality undiscovered gems built around smaller players with robust financial traits.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com